Apellis Pharmaceuticals, Inc. (APLS) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Waltham, MA, 미국. 현재 CEO는 Cedric Francois.
APLS 을(를) 보유 IPO 날짜 2017-11-09, 705 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $5.22B.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. The company's lead product, pegcetacoplan, is in Phase III clinical trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, with the approved product EMPAVELI addressing multiple rare hematologic, nephrologic, and neurologic indications. Apellis maintains a robust pipeline including APL-2006, a bispecific C3 and VEGF inhibitor, and APL-1030, a C3 inhibitor for neurodegenerative diseases, supported by strategic collaborations with Swedish Orphan Biovitrum AB and Beam Therapeutics. Founded in 2009 and headquartered in Waltham, Massachusetts, the company is advancing complement-inhibition science across multiple therapeutic areas with significant unmet medical needs.
